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Precis 
 Breast cancer patients are at highest VTE risk within the first year of diagnosis, but remain at 
2-fold increased risk many years after. 
 Temporal associations with patient, tumor and treatment characteristics provide insight into 
the time-dependent etiology of VTE in breast cancer patients. 
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Abstract 
Background: Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. 
We assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis.  
Methods: A Swedish population-based study including 8338 breast cancer patients diagnosed from 
2001-2008 in the Stockholm-Gotland region, with complete follow-up until 2012. Incidence of VTE 
was compared with that of 39013 age-matched reference individuals from the general population. Cox 
and flexible parametric models were used to examine associations with patient, tumor and treatment 
characteristics, accounting for time-dependent effects.  
Results: Over a median follow-up of 7.2 years, 426 breast cancer patients experienced a VTE event 
(cumulative incidence = 5.1%). VTE incidence was 3-fold increased (HR = 3.28; 95% CI = 2.87-3.74) 
compared to the general population and was highest 6 months after diagnosis (HR = 8.62; 95% CI = 
6.56-11.33) with a sustained increase in risk thereafter (HR at 5 years = 2.19; 95% CI = 1.80-2.67). 
Independent predictors of VTE were older age, being overweight, pre-existing VTE, comorbid 
disease, tumor size > 40 mm, progesterone receptor (PR) negative status, > 4 affected lymph nodes, 
and receipt of chemo- and endocrine therapy. The impact of chemotherapy was limited to early-onset 
VTE, while comorbid and PR negative disease were more strongly associated with late-onset events. 
Conclusions: Our study confirms the long-term risk of VTE in breast cancer patients, and identifies a 
comprehensive set of clinical risk predictors. Temporal associations with patient, tumor and treatment 
characteristics inform about the time-dependent etiology of VTE. 
 
Key words: breast cancer, epidemiology, venous thromboembolism, predictors, time-dependent risk 
modeling. 
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Introduction   
Venous thromboembolism (VTE) is a major health problem affecting ~1-2 per 1000 individuals per 
year 
1, 2
. Breast cancer patients are at 3- to 4-fold increased risk of developing VTE compared to 
women without cancer 
3, 4
. Although VTE risk is relatively low in breast cancer patients compared to 
other cancer populations, long-term consequences in terms of morbidity 
5, 6
 and quality of life 
7
 are 
substantial, especially for non-metastatic patients who have a rather good prognosis. Moreover, as one 
of the most common cancers, breast cancer contributes to a large number of cancer-related VTE cases 
and associated healthcare costs 
8
.  
Several studies have examined the incidence of VTE in breast cancer patients 
3, 4, 9, 10
, all showing an 
excess risk shortly after diagnosis, but with a potential sustained increase in risk thereafter 
4
. The risk 
of VTE increases with advanced clinical stages 
3, 4, 9
 and randomized clinical trials (RCTs) have 
reported higher VTE rates during treatment with chemo- and endocrine therapy 
11-13
. Few studies, 
however, have assessed the independent contribution of tumor, treatment and other patient-related 
factors to VTE risk and little is known about predictors of early vs. late-onset events. Chemotherapy, 
for instance, has been suggested to influence short-term risk only 
 10, 14, 15
, while tumor-specific factors 
associated with locoregional recurrence and distant metastasis 
16, 17
 may have a larger impact on long-
term VTE risk, given the close interrelation between cancer progression and activation of the 
coagulation system.
18, 19
 Identification of time-dependent risk factors is also relevant for the timing of 
preventive strategies, including early detection and short-term prophylaxis covering periods of highest 
risk. 
In the present study we aimed to assess the risk and predictors of VTE in a population-based breast 
cancer cohort, by time since diagnosis. We studied the impact of routinely available clinical 
parameters, which can easily be incorporated into future risk stratification models.   
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Methods 
 
Breast cancer cohort 
Our source population comprised women diagnosed with primary invasive breast cancer between 2001 
and 2008 in the Stockholm-Gotland region, as identified through the Stockholm Breast Cancer 
Register. The register has about 99% completeness and provides detailed information on 
tumor/treatment characteristics, and routine follow-up on locoregional recurrences and distant 
metastases 
20
. For the present study, we included patients diagnosed at age 25-75 years without distant 
metastasis at diagnosis (N = 8338). The cohort was linked by the unique personal identity number to 
the Cancer Register, Patient Register, Cause of Death Register and Total Population Register and 
follow-up was complete until 31 December 2012. We also performed linkage with the Prescribed 
Drug Register which contains data on all drugs dispensed from Swedish pharmacies from July 2005 
onward. Self-reported information on weight and height [from which body mass index (BMI) was 
calculated] was available for a subset of 4687 patients who were invited in 2009 to participate in 
Libro-1, a study aimed at identifying risk and prognostic factors for breast cancer 
21
. The study was 
approved by the Regional Ethical Review Board in Stockholm and all Libro-1 participants gave 
written informed consent. 
 
Age-matched reference individuals 
We assembled a comparison cohort based on the Total Population Register with cross-linkage to the 
Cancer Register, Patient Register, Cause of Death Register and Prescribed Drug Register as described 
above. The Total Population Register contains information on area of residence, vital status and dates 
of immigration and emigration for all Swedish residents. For each patient, we randomly sampled up to 
5 women from the general population living in the Stockholm-Gotland region matched on birth year. 
Each reference individual was alive and free of breast cancer on the date of the matched patient’s 
diagnosis (the index date). In total, 2677 women could not be matched to an index case, resulting in 
39013 age-matched reference individuals. The latest cross-linkage of the Total Population Register to 
the different health registers was performed at 31 December 2010. Hence, follow-up was shorter in 
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matched cohort (breast cancer cohort and age-matched population cohort) than case-only (breast 
cancer cohort) analyses. 
 
Venous thromboembolism 
VTE events were identified through the Patient Register, which has nationwide coverage since 1987 
and includes all inpatient hospitalizations in Sweden 
22
. Since 2001, Swedish counties are also obliged 
to report hospital-based outpatient physician visits. VTE was defined as a diagnosis of deep vein 
thrombosis (DVT) or pulmonary embolism (PE) according to International Classification of Diseases 
codes as described previously 
23
 (Supplementary Table 1). The definition of DVT included diagnoses 
of lower and upper extremity thrombosis, as well as thrombosis in other specified veins including 
those of the thorax and abdomen. 
 
Clinical characteristics 
The following variables were extracted from the Stockholm Breast Cancer Register: tumor size, 
histological grade, estrogen/progesterone receptor (ER/PR) status, number of affected lymph nodes, 
type of surgery, radiotherapy, and receipt of chemo/endocrine therapy, all referring to the date of the 
primary cancer. Tumor and treatment information was essentially complete (< 5% of the patients had 
missing data), except for ER (7.3% missing) and PR status (8.9% missing). Grade was routinely 
collected from 2004 onwards and was missing for 39.3% of the patients. VTE events prior to the index 
date were identified through the Patient Register. Comorbid conditions were also extracted and 
summarized into the Charlson Comorbidity Index score.
24
   
 
Statistical analyses 
We first assessed the risk of VTE in breast cancer patients as compared to age-matched reference 
individuals in matched cohort analysis. Numbers of person-years at risk were calculated from the 
breast cancer diagnosis and corresponding index date in the age-matched reference individuals until 
the date of the first VTE event, death, emigration, or 31 December 2010 whichever came first. 
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Cumulative incidences were visualized using Kaplan-Meier plots. Because of the time-dependent risk 
pattern, time-specific hazard ratios were estimated using flexible parametric survival models (FPM) 
25
 
with time since index date as underlying time scale. FPM uses a restricted cubic spline function to 
model the baseline hazard and is similar to the Cox proportional hazards model in that it provides a 
hazard ratio (HR) as measure of association. An advantage of FPM is that non-proportional hazards 
can easily be fitted by adding a spline for the interaction with time.  
Next, we studied the impact of patient, tumor and treatment characteristics in case only analysis using 
Cox proportional hazards models. Person-time was defined as described above starting from the date 
of diagnosis, but with extended follow-up until 31 December 2012, as this analysis concerned breast 
cancer patients only. Proportional hazards assumptions were verified using tests for Schoenfeld 
residuals and in case of non-proportionality, time-dependent effects were modelled using FPM. We 
conducted three analyses to study the impact of each clinical parameter: 1. a model adjusting for age at 
diagnosis only; 2. three grouped models, including respectively all patient, tumor and treatment 
characteristics with additional adjustment for age at diagnosis, and 3. a multivariable model including 
all variables.  
Three sensitivity analyses were performed. First, we repeated the matched cohort analysis using a 
more refined outcome definition in patients diagnosed after July 2005. To increase specificity, we only 
included VTE diagnoses followed by a prescription of vitamin K antagonists (ATC = B01AA) or 
heparins (ATC = B01AB) within 90 days or death within 30 days of the VTE event. A second 
sensitivity analysis was carried out to evaluate the long-term risk associated with the first primary 
tumor. For this analysis, person-time was additionally censored at locoregional recurrence, distant 
metastasis and diagnosis of a new primary breast cancer. Finally, we repeated all analyses in patients 
without pre-existing VTE.  
 
Results 
Descriptive characteristics of the breast cancer and age-matched population cohort are summarized in 
Table 1. Mean age at breast cancer diagnosis was 57.1 years and 426 patients experienced a VTE 
event during a median follow-up of 7.2 years. Mean age at VTE diagnosis was lower in breast cancer 
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patients (62.0 years) than in age-matched reference individuals (65.3 years). The 1, 2 and 5-year 
cumulative incidences of VTE in the breast cancer cohort were 2.0, 2.5 and 4.0%. Corresponding 
cumulative incidences in the age-matched population cohort were 0.3, 0.5 and 1.1% respectively 
(Figure 1). VTE rates were 7.9 per 1000 person-years for the breast cancer cohort and 2.4 per 1000 
person-years in the age-matched reference individuals (Supplementary Table 2).  
Overall, breast cancer patients experienced a 3-fold increased risk of VTE compared to the age-
matched reference individuals [HR (95% CI) = 3.28; 2.87-3.74]. The relative risk of VTE was highest 
the first 6 and 12 months after diagnosis [HR (95% CI) = 8.62 (6.56-11.33) and 4.46 (3.52-5.66) 
respectively], and was more or less constant thereafter [HR (95% CI) at 2, 5, 7 years = 2.01 (1.50-
2.70), 2.19 (1.80-2.67) and 2.26 (1.70-2.99) respectively] (Table 2). Separate analyses for DVT and 
PE resulted in HRs similar to those for VTE.  
Table 3 lists the HRs for VTE by patient, tumor and treatment characteristics. Older age at diagnosis, 
BMI ≥ 25 kg/m2, pre-existing VTE, tumor size > 40 mm, progesterone receptor (PR) negative disease, 
> 4 affected lymph nodes and chemotherapy were all associated with an increase in VTE risk in 
multivariable analyses. Models with stepwise adjustment showed that the impact of patient, tumor and 
treatment characteristics was robust, except for comorbidities and breast-conserving surgery which 
showed no association with VTE after multivariable adjustment. 
The proportional hazards assumption was not met for comorbid disease, PR status and chemotherapy 
(Figure 2, Supplementary Table 3). While not reaching significance in terms of overall VTE risk, 
comorbid conditions were associated with late-onset events occurring 5 years after diagnosis. 
Similarly, PR-negative tumors showed a stronger association with late-onset VTE. Chemotherapy, on 
the other hand, was only associated with events occurring within the first year of diagnosis.  
No major difference in risk was observed between chemotherapy alone and combined chemo- and 
endocrine therapy. VTE risks were also similar when comparing tamoxifen versus aromatase 
inhibitors (AIs) alone, but AI use tended to show a stronger association with VTE when combined 
with chemotherapy (Supplementary Table 4).  
Sensitivity analyses using a more refined definition generated somewhat lower VTE rates, but HRs 
consistent with those observed in the main analysis (Supplementary Table 5). The long-term VTE 
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risk remained present when censoring person-time at disease recurrence and new breast cancer 
diagnoses: i.e. the risk associated with the primary tumor was only slightly attenuated 7 years after 
diagnosis with a HR of 1.76 (Supplementary Table 6). Relative risks of VTE were also similar in 
analyses excluding patients with a VTE history (Supplementary Table 7), as were associations with 
individual patient, tumor and treatment characteristics (Supplementary Table 8).  
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Discussion 
 
In this population-based study, we demonstrate that breast cancer patients are at highest VTE risk 
within the first year of diagnosis, but remain at 2-fold increased risk for many years after. Older age at 
diagnosis, being overweight, VTE history, comorbid conditions, a larger tumor size, PR-negative 
disease, lymph node involvement, and receipt of chemo- and endocrine therapy were all independent 
predictors of VTE in breast cancer patients. The impact of most predictors was constant over time 
except for chemotherapy, comorbid disease and PR status, which showed differential associations with 
early and late-onset events.  
 
Consistent with previous reports 
3, 4, 9
, the incidence of VTE was highest in the first 6 to 12 months 
after diagnosis. The observed absolute risks are also similar to recent estimates reported by Walker et 
al.
10
 incorporating in- and outpatient diagnoses. Long-term risk data, however, are scarce, although a 
Danish study 
4
 previously indicated a potential sustained increase in risk with HRs being significant 
beyond 2 years of diagnosis. Our study is the first to confirm the long-term risk of VTE in breast 
cancer patients, with relative risks remaining 2-fold increased for at least 7 years. Importantly, we 
could address the impact of the primary tumor, as recurrent disease and treatment can result in inflated 
long-term risk estimates.  
 
The strong impact of chemotherapy on VTE risk is consistent with previous reports showing an excess 
risk in chemotherapy-treated patients, independent of cancer site and stage 
4, 9, 26, 27
. Several 
mechanisms have been proposed for the high thrombogenic potential of chemotherapy, including 
damage to endothelial cell walls, decreased fibrinolytic activity of the blood and use of venous 
catheters for chemotherapy administration 
28, 29
. In line with RCT data 
12, 30
 and observational data by 
Walker et al. 
10
, the effect of chemotherapy was limited to the period of active treatment. A higher 
VTE incidence was also found with endocrine therapy. Trials comparing tamoxifen versus AIs have 
reported higher VTE rates with tamoxifen use 
13
. In this observational study, no difference by type of 
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endocrine treatment was found; although there was some tendency of a higher VTE risk with AI use in 
chemotherapy-treated patients. This could be the consequence of a higher baseline risk in 
postmenopausal AI users 
10
 and/or preferential prescriptions of AIs to patients for whom tamoxifen is 
contraindicated because of a personal or family history of thrombosis, or other VTE risk factors 
31
. We 
also note the particular high risk of VTE in AI users who received chemotherapy, although the 
underlying mechanism is unclear and requires further investigation. 
 
Markers of tumor aggressiveness have previously been linked to VTE risk 
3, 10
, but little is known 
about the independent contribution of tumor-specific factors after accounting for treatment effects. We 
found a positive association with tumor size and PR negative disease in multivariable analyses. Since 
both factors are established markers of disease recurrence 
16, 17
, these data agree with a close interplay 
between tumor progression and prothrombotic processes 
18, 19
. The lack of association with ER status 
can be explained by the adverse effect of endocrine therapy, which might have offset a protective 
effect of ER-positive disease. Interestingly, the impact of PR-negative tumors was stronger for late-
onset VTE. Although the nature of this temporal association remains to be determined, PR absence has 
been associated with resistance to endocrine therapy 
32
. In addition, ER-positive/PR-negative tumors 
are characterized by more aggressive features and worse outcomes compared to ER-positive/PR-
positive tumors 
33
. Previous studies have also reported increased VTE rates with lymph node 
involvement 
3, 10
, but the predictive value of this tumor characteristic has been questioned due to lack 
of adjustment for chemotherapy 
34
. Despite the slight attenuation in multivariable analyses, extensive 
nodal involvement remained an independent predictor of VTE in our study. 
 
We further observed independent associations with older age and increasing BMI, which have been 
reported previously 
3, 4, 10
. Comorbid disease also predicted VTE risk, but only 5 years after diagnosis. 
Since short-term VTE risk is dominated by breast cancer treatment, this could have masked an 
independent effect of comorbid disease early after disease onset. The lack of a gradual increase in 
VTE risk with increasing comorbidity burden suggests that specific conditions are likely to have a 
12 
 
stronger influence than an aggregated score, which could be evaluated further in future larger scale 
studies.   
 
Thromboprophyaxis leads to a reduction in VTE incidence in cancer patients 
35, 36
, but is not 
recommended on a routine basis in breast cancer patients due to the low baseline risk and side effect 
associated with thromboprophyaxis, namely bleeding 
37
. Selected high-risk patients, however, could 
potentially benefit from prophylactic or early detection measures. Several risk prediction models have 
been developed for identifying high-risk patients, of which the Khorana model is the most established 
38
. Although this model includes cancer site, it does not account for cancer-specific risk factors. Since 
VTE risk profiles differ by cancer site 
10, 39
, cancer specific models are needed in order to optimize risk 
assessment. The clinical predictors identified by our study may thus facilitate future risk stratification 
in the breast cancer setting. Further studies, however, are needed to assess the added value of other 
laboratory parameters, such as leukocytosis and thrombocytosis, on top of the risk predictors identified 
here. 
 
The present study is characterized by a large population-based design and linkage to register-based 
data which minimizes information bias. Other strengths are the detailed information on patient, tumor 
and treatment characteristics and use of FPM for capturing time-dependent effects. We also 
acknowledge several limitations. Although the Patient Register has high validity for cardiovascular 
diagnoses including VTE, misclassification may have occurred. In agreement with previous reports 
40, 
41
, ~89% of all cases were confirmed using prescription and death records. Sensitivity analyses 
showed no evidence of differential misclassification, despite the somewhat lower absolute rates. 
Second, outpatient diagnoses are only registered from 2001 onward. For this reason, some patients 
treated as disease-free may have had a VTE history at diagnosis. Risk estimates were, however, not 
materially different after excluding patients with pre-existing VTE. Third, BMI was the only variable 
assessed after diagnosis. We cannot rule out post-diagnostic changes in BMI, but class effects are 
considered unlikely. The observed association with overweight is also consistent with previous data 
10
. 
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Finally, it should be noted that cancer patients are subject to increased medical surveillance, resulting 
in inflated HRs close to diagnosis. This bias is unlikely to extend beyond 1 year of follow-up, and 
cannot explain the long-term risk pattern observed. 
 
In conclusion, our study confirms the long-term VTE risk in breast cancer patients, and identifies a 
comprehensive set of clinical risk predictors, which may facilitate future risk stratification and 
prevention efforts. Our findings also provide novel insights into the time-dependent etiology of VTE 
in breast cancer patients, underscoring the importance of early and late-onset differentiation in VTE 
risk prediction.   
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Figure legends 
 
Figure 1. Cumulative incidence of VTE in breast cancer patients as compared to age-matched 
reference individuals from the general population.  
 
Abbreviations: CI = confidence interval; HR = hazard ratio. Cumulative incidence estimates as 
obtained with Kaplan-Meier survival analysis with time since index date as underlying time scale.  
 
 
Figure 2. Time-dependent effects of comorbidity, PR-negative disease and chemotherapy  on VTE 
risk in breast cancer patients. 
 
Abbreviations: CI = confidence interval; HR = hazard ratio. Time-dependent hazard ratios as 
estimated with flexible parametric survival models with time since diagnosis as underlying time scale: 
A = comorbid conditions (REF = no comorbid disease); B = Progesterone receptor (PR) status (REF = 
PR-positive tumors); C = chemotherapy (REF = no chemotherapy). All hazard ratios are multivariable 
adjusted.  
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Table 1. Characteristics of the study population. 
 
Characteristics Breast cancer cohort  
(N = 8338) * 
Matched population cohort 
(N = 39013) 
Age at diagnosis (years)   
  Mean (SD) 57.1 (10.3) 57.3 (10.2) 
  Min-Max 25-75 25-75 
Years of follow-up, median (IQR) 7.2 (4.3) / 5.3 (4.1) 5.9 (4.0) 
No. of events:   
  VTE 426 / 364 555 
   Pulmonary embolism 179 / 141 227 
   Deep vein thrombosis 262 / 235 358 
Age at VTE diagnosis (years), mean (SD) 62.9 (10.4) / 62.0 (10.1) 65.3 (9.2) 
 
Abbreviations:  CI = confidence interval; ICD = international classification of diseases; SD = standard deviation; IQR = 
interquartile range; VTE = venous thromboembolism * For the Stockholm-Gotland breast cancer cohort, descriptive statistics 
of incident VTE are given for the entire follow-up in case only analysis (until 31 December 2012), and the end of follow-up 
in matched cohort analysis (until 31 December 2010) Descriptive statistics of incident VTE in the age-matched population 
cohort are given until 31 December 2010 (matched cohort analysis). 
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Table 2. Relative risk of venous thromboembolism in breast cancer patients compared to age-matched reference individuals from the general population, 
overall and at specific time points after the index date. 
 
  HR (95% CI)       
  Overall At 6 months At 1 year At 2 years At 5 years At 7 years At 9 years 
 N total/VTE *        
Matched population cohort 39013/555 REF (1.00) REF (1.00) REF (1.00)  REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
Breast cancer cohort 8338/364 3.28 (2.87-3.74) 8.62 (6.56-11.33) 4.46 (3.52-5.66) 2.01 (1.50-2.70) 2.19 (1.80-2.67) 2.26 (1.70-2.99) 2.19 (1.55-3.09) 
 N total/DVT *        
Matched population cohort 39013/358 REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
Breast cancer cohort 8338/235 3.25 (2.75-3.83) 9.81 (6.70-13.81) 3.68 (2.64-5.13) 1.69 (1.17-2.43) 2.07 (1.58-2.71) 2.24 (1.54-3.25) 2.22 (1.42-3.47) 
 N total/PE *        
Matched population cohort 39013/227 REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
Breast cancer cohort 8338/141 3.09 (2.50-3.81) 7.21 (4.62-11.26) 4.68 (3.26-6.71) 2.55 (1.67-3.87) 2.25 (1.70-2.99) 2.23 (1.48-3.37) 2.12 (1.25-3.61) 
 
Abbreviations: HR = hazard ratio; CI = confidence interval; VTE = venous thromboembolism; DVT = deep vein thrombosis; PE = pulmonary embolism. Hazard ratios as estimated using 
flexible parametric survival models. Follow-up started from the breast cancer diagnosis and corresponding index date in the age-matched reference individuals and follow-up was complete until 
December 2010. * No. of incident VTE events is lower than in the Stockholm-Gotland breast cancer cohort with extended follow-up until December 2012.  
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Table 3. Association of patient, tumor and treatment characteristics with risk of venous 
thromboembolism risk in breast cancer patients. 
 
  HR (95% CI) 
 N total/VTE Model 1 Model 2 Model 3 
Patient characteristics 
Age at diagnosis (years)     
  < 50  1857/66 REF (1.00) REF (1.00) REF (1.00) 
  50-59  2639/119 1.21 (0.90-1.64) 1.24 (0.91-1.67) 1.35 (0.99-1.83) 
  60-69  2875/174 1.73 (1.30-2.30) 1.70 (1.28-2.26) 1.98 (1.47-2.66) 
  > 69  967/67 2.11 (1.50-2.97) 1.79 (1.27-2.54) 2.17 (1.51-3.14) 
BMI (kg/m
2
)     
  <25  2546/94 REF (1.00) REF (1.00) REF (1.00) 
  25-30  1557/79 1.38 (1.02-1.86) 1.38 (1.02-1.86) 1.37 (1.01-1.85) 
  > 30  584/37 1.71 (1.17-2.50) 1.64 (1.11-2.40) 1.60 (1.09-2.35) 
Pre-existing VTE     
  No 8189/382 REF (1.00) REF (1.00) REF (1.00) 
  Yes 149/44 11.06 (8.08-15.14) 10.69 (7.80-14.66) 11.56 (8.39-15.92) 
Comorbidities *     
  None 7385/360 REF (1.00) REF (1.00) REF (1.00) 
  1 514/38 1.42 (1.02-2.00) 1.27 (0.90-1.77) 1.28 (0.91-1.80) 
  ≥ 2 439/28 1.30 (0.88-1.92) 1.14 (0.77-1.69) 1.16 (0.78-1.73) 
Tumor characteristics 
Tumor size (mm)     
  ≤ 10 2086/93 REF (1.00) REF (1.00) REF (1.00) 
  11-20 3555/174 1.14 (0.88-1.46) 1.14 (0.88-1.49) 1.08 (0.83-1.41) 
  21-40 1924/106 1.37 (1.04-1.81) 1.20 (0.88-1.63) 1.13 (0.83-1.55) 
  >40 514/43 2.22 (1.55-3.20) 1.71 (1.15-2.53) 1.55 (1.02-2.35) 
Tumor grade (Elston)     
  Low 963/38 REF (1.00) REF (1.00) REF (1.00) 
  Moderate 2557/119 1.19 (0.83-1.71) 1.03 (0.71-1.49) 0.95 (0.65-1.38) 
  High 1539/73 1.35 (0.91-2.00) 1.01 (0.66-1.54) 0.85 (0.56-1.31) 
Estrogen receptor status     
  Positive 6353/313 REF (1.00) REF (1.00) REF (1.00) 
  Negative 1376/76 1.22 (0.95-1.57) 0.96 (0.71-1.31) 1.06 (0.66-1.70) 
Progesterone receptor status *     
  Positive 5176/236 REF (1.00) REF (1.00) REF (1.00) 
  Negative 2419/143 1.38 (1.12-1.70) 1.32 (1.03-1.70) 1.33 (1.03-1.71) 
No. of affected lymph nodes       
  0 5033/225 REF (1.00) REF (1.00) REF (1.00) 
  1-4 2241/113 1.21 (0.97-1.52) 1.16 (0.92-1.47) 0.99 (0.76-1.28) 
  > 4 714/67 2.53 (1.92-3.33) 2.18 (1.62-2.94) 1.73 (1.21-2.46) 
Treatment characteristics     
Surgery      
  Total mastectomy 3205/178 REF (1.00) REF (1.00) REF (1.00) 
  Breast-conserving 5014/242 0.81 (0.67-0.98) 0.79 (0.62-1.01) 1.08 (0.81-1.45) 
Radiotherapy     
  No 1882/89 REF (1.00) REF (1.00) REF (1.00) 
  Yes 6318/330 1.16 (0.92-1.46) 1.32 (0.99-1.76) 1.07 (0.79-1.47) 
Chemo/endocrine therapy *     
  None 355/11 REF (1.00) REF (1.00) REF (1.00) 
  Endocrine only 4475/208 1.60 (0.87-2.94) 1.59 (0.87-2.92) 1.86 (0.94-3.72) 
  Chemo only  1119/66 2.77 (1.45-5.26) 2.58 (1.35-4.93) 2.42 (1.24-4.73) 
  Chemo plus endocrine 2230/131 2.67 (1.43-4.97) 2.45 (1.31-4.58) 2.74 (1.33-5.63) 
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Abbreviations: BMI = body mass index, CI = confidence interval; HR = hazard ratio; VTE = venous thromboembolism. 
Hazard ratios as estimated from Cox proportional hazard models with time since diagnosis as underlying time scale. Model 1: 
adjusted for age at diagnosis; Model 2: grouped models including respectively all patient, tumor and treatment characteristics 
with additional adjustment for age at diagnosis; Model 3: multivariable adjusted models including all variables listed in the 
table. * Variables not meeting the proportional hazards assumption.  
